Skip to content

The clinical application of thunder-fire moxibustion to breast cancer chemotherapy-induced nausea and vomiting

The clinical application of thunder-fire moxibustion to breast cancer chemotherapy-induced nausea and vomiting

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100004292
Enrollment
Unknown
Registered
2021-01-19
Start date
2021-02-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bresst cancer

Interventions

Sponsors

The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) Patients are informed, agree and sign the Informed Consent, voluntarily participate in this observation study, comply with the researcher's needs, promise to accept the treatment and safety observation, and facilitate follow-up. (2) For females, the youngest is 18 years old and the oldest is 75 years old. (3) Breast cancer diagnosed after pathological examination. (4) Patients who have completed at least 3 chemotherapy cycles. (5) Pre-chemotherapy evaluation card score is greater than or equal to 60. (6) Breast cancer patients who received EC (cyclophosphamide + epirubicin) hyperemetic chemotherapy. (7) Blood images, liver and kidney functions before chemotherapy were in the normal range, meeting the basic indications and requirements of chemotherapy. (8) Lucid, no serious hearing impairment, a certain degree of comprehension and language skills.

Exclusion criteria

Exclusion criteria: (1) Language barrier preventing sufficient communication ability. (2) Nausea or vomiting within 24 hours before chemotherapy. (3) Patients with severe or uncontrolled organic lesions or infections, such as decompensated heart, liver, lung, or renal failure. (4) Persons suffering from uncontrollable mental illness or mental disorder (5) Patients with obstruction of the digestive tract. (6) Metastasized breast cancer. (7) Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
KPS score;grade of nausea, vomiting and appetite;TCM clinical syndrome score;

Secondary

MeasureTime frame
CINV risk assessment for breast cancer;life function index scale;

Countries

China

Contacts

Public ContactWanling Liu

The First Affiliated Hospital of Guangzhou University of Chinese Medicine

992642040@qq.com+86 15323394982

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026